Pharmaceuticals

Ceva Santé Animale calls to speed up development of critical new vaccines at VIV Asia 2023

LIBOURNE, France, March 7, 2023 /PRNewswire/ -- Ceva Santé Animale, (Ceva), the #5 animal health company present in 110 countries, participates in the VIV Asia inBangkok, Thailand. Earlier today, the One Health company held the "Ceva Innovation Day" pre-opening symposium, featuring a keynote spee...

2023-03-07 12:00 3106

GenScript ProBio Congratulates Eutilex's IND Clearance from MFDS

NANJING, China, March 7, 2023 /PRNewswire/ -- Recently, Eutilex, a partner of GenScript ProBio, announced MFDS(Ministry of Food and Drug Safety) clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio extends congratulations o...

2023-03-07 10:00 2025

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001

SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today...

2023-03-06 21:00 1989

Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published

SUZHOU, China, March 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that the study ...

2023-03-03 14:56 2580

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

LONDON and HONG KONG, March 2, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB')  to provide strategic input based on their scientific knowledge and c...

2023-03-02 20:00 2571

Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376

SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shanghai Allist Pharmaceuticals Co., Ltd., ("Allist" hereafter) for the further ...

2023-03-02 19:15 2894

DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY

Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor LAUSANNE, Switzerland, March 2, 2023 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), an independent Swiss-based, biopharmaceutical company ...

2023-03-02 09:00 2636

ClinChoice Acquires CROMSOURCE, Expanding its Global Presence

PHILADELPHIA, SHANGHAI and VERONA, Italy, March 2, 2023 /PRNewswire/ -- ClinChoice Medical Development is pleased to announce its acquisition of CROMSOURCE S.r.l., an ISO-certified full-service contract research organization with its corporate headquarters inVerona, Italy and its US headquarters ...

2023-03-02 04:12 2749

Cambrex Recognized with CDMO Leadership Awards for 9th Consecutive Year

EAST RUTHERFORD, N.J., March 1, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized with 2023 CDMO Leadership Awards in the categories of Quality, Service, Expertise, and Compatibility. Additionally...

2023-03-01 19:00 2129

A promising picture for multi-cancer early detection in Southeast Asia - latest update from biotech firm Gene Solutions

HO CHI MINH CITY, Vietnam, March 1, 2023 /PRNewswire/ -- In January 2023, Vietnam's Medical Genetics Institute & Gene Solutions  published their research paper on Cancer Investigation:Clinical validation of a ctDNA-based assay for multi-cancer detection: an interim re...

2023-03-01 09:30 2179

Global Cold Chain Transport Track & Trace Revenues in Pharma to Reach US$2.9 billion by 2027

For pharmaceutical companies to ensure product integrity and maintain regulatory compliance, deeper product monitoring, enhanced cold chain infrastructure, and focused automation will be critical NEW YORK, Feb. 28, 2023 /PRNewswire/ -- The global pharmaceutical (pharma) industry will surpassUS$1...

2023-02-28 21:30 1681

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of JWATM214 in patients with advanced hepato...

2023-02-28 17:30 2205

Chula's AICute - An Assessment Tool for Ischemic Stroke Risk

A research team from the Faculty of Medicine and Faculty of Engineering, Chulalongkorn University has jointly developed AICute, an innovative program to assess the chance of stroke caused by heart disease (Ischemic Stroke), aimed at helping hospitals that lack cardiologists to enhance the effecti...

2023-02-28 12:24 2128

On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy

YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023'...

2023-02-28 09:16 2498

CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma

* This supplementary new drug application was filed for the fourth indication for sugemalimab inChina, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma. If approved, sugemalimab would be the first PD-L1 monoclo...

2023-02-28 08:05 3900

Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration

ROCKVILLE, Md. and SUZHOU, China, Feb. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2023-02-28 08:00 3372

Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today held a ceremony to celebrate the initiation of operations a...

2023-02-28 07:30 4565

Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective from March 13, 2023. HSHKBIO selects securities of multiple listed co...

2023-02-27 17:15 2531

Turacoz Paves the Way in Digital Content Management for Healthcare Communications with Veeva & Expert Training

UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital content gains importance in healthcare, the medical writing industry is transitioning to digital content management. Turacoz is setting the standar...

2023-02-27 17:07 1595

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS * Total Group revenue $160.1M ...

2023-02-27 14:37 1742
1 ... 42434445464748 ... 181